Zacks Investment Research upgraded Pacific Biosciences of California (NASDAQ:PACB) to Hold in a report released today.
- Updated: November 29, 2016
Yesterday Pacific Biosciences of California (NASDAQ:PACB) traded -0.13% lower at $7.75. The company’s 50-day moving average is $8.15 and its 200-day moving average is $8.49. The last stock close price is down -9.33% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same time. 501,711 shares of the stock were exchanged, down from an average trading volume of 1,053,480
Zacks Investment Research has upgraded Pacific Biosciences of California (NASDAQ:PACB) to Hold in a report released on Tuesday November 29, 2016.
Previously on 02/04/2016, Piper Jaffray reported about Pacific Biosciences of California (NASDAQ:PACB) raised the target price from $9.00 to $11.00. At the time, this indicated a possible downside of -0.11%.
See Chart Below
Pacific Biosciences of California has a 52 week low of $6.61 and a 52 week high of $14.00 The company’s market cap is currently $0.
In addition to Zacks Investment Research reporting its target price, a total of 6 firms have reported on the stock. The consensus target price is $12.50 with 3 firms rating the stock a strong buy, 1 firm rating the stock a buy, 2 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.
About Pacific Biosciences of California (NASDAQ:PACB)
Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company's Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes. Based on its SMRT technology, the Company has introduced the PacBio RS II System. It offers The SMRT Cell, Phospholinked nucleotides and The PacBio RS II and Sequel instruments. Based on the Company's SMRT sequencing technology, its products enable de novo genome assembly to finish genomes in order to identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms and find genes; targeted sequencing to characterize genetic variations, and deoxyribonucleic acid (DNA) base modification identification to help characterize epigenetic regulation and DNA damage.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.